Everything below concerns visceral adiposity. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-06. Numbers and descriptions here follow the published literature rather than marketing material.
Several compounds share the GHRH framework, including sermorelin, the shorter 1-29 fragment, and other analogs built on the full 1-44 chain. Naming follows a common convention: a stem that identifies the peptide plus a suffix marking analog status. Reports may describe tesamorelin by its sequence fragment, as a GHRH(1-44) analog, or by its amino-terminal modification. Indexing the compound therefore requires searching all of these forms, since some older literature predates the current international nonproprietary name.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from truncated or oxidized forms. Mass spectrometry confirms the expected molecular weight, and peptide mapping after enzymatic digestion verifies the amino acid sequence. Water content is measured because residual moisture affects stability, and tests for aggregates or particulates are standard for injectable peptides. Circular dichroism can indicate whether the molecule has adopted an unexpected secondary structure in solution.
Research supply is often accompanied by a certificate of analysis listing chromatographic purity, mass confirmation, and storage conditions. Laboratories compare that document with an independent test when material is intended for bench work, since certificates describe a batch rather than an individual vial. Published studies usually state the source and purity of the peptide because small differences in purity can shift measured activity. Full analytical validation is rarely reported, which leaves batch-to-batch comparability an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | GHRH analog family |
| Residue count | 44 amino acids | Matches human GHRH(1-44) backbone |
| N-terminal group | trans-3-hexenoyl | Main structural difference from native hormone |
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility class | Freely soluble in water | Peptide character; less soluble in organic solvents |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
Growth hormone released from the pituitary stimulates the liver and other tissues to produce insulin-like growth factor 1, a stable circulating protein that serves as a practical marker of activity. Clinical studies therefore track IGF-1 concentrations alongside the hormone itself, and they commonly measure body composition with imaging rather than relying on body weight alone. Visceral adipose tissue, the fat surrounding abdominal organs, is quantified by computed tomography in the studies that supported approval. Adverse effects reported in trials include injection-site reactions, joint pain, and increases in blood glucose, which is why monitoring accompanies use.
Questions remain about how much of the observed fat reduction reflects direct GHRH-receptor signaling versus the downstream growth hormone and IGF-1 surge. It is also unclear whether the compound produces meaningful benefit in populations without lipodystrophy, since trials in cognitive impairment did not reach their stated goals. Long-term effects on glucose metabolism and on cardiovascular outcomes are not fully characterized. Published work generally describes effects on surrogate markers rather than on hard clinical endpoints, and independent replication of some findings is limited.
Tesamorelin acts on the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in intracellular cyclic AMP, which in turn opens ion channels and raises calcium concentrations, leading to release of stored growth hormone into the bloodstream. Because the peptide works through the same receptor as the body's own GHRH, the resulting secretion follows a pulsatile pattern rather than a continuous elevation. The N-terminal modification slows enzymatic breakdown, so the signal persists longer than it would with the unmodified hormone.
=== Bibliography === Ashby, Michael; Hugh Shercliff; David Cebon (2007). Materials: engineering, science, processing and design (1st ed.). Butterworth-Heinemann. ISBN 978-0-7506-8391-3. Askeland, Donald R.; Pradeep P. Phulé (2005). The Science & Engineering of Materials (5th ed.). Thomson-Engineering. ISBN 978-0-534-55396-8. Callister, Jr., William D. (2000). Materials Science and Engineering – An Introduction (5th ed.). John Wiley and Sons. ISBN 978-0-471-32013-5. Eberhart, Mark (2003). Why Things Break: Understanding the World by the Way It Comes Apart. Harmony. ISBN 978-1-4000-4760-4. Gaskell, David R. (1995). Introduction to the Thermodynamics of Materials (4th ed.). Taylor and Francis Publishing. ISBN 978-1-56032-992-3. González-Viñas, W. & Mancini, H.L. (2004). An Introduction to Materials Science. Princeton University Press. ISBN 978-0-691-07097-1. Gordon, James Edward (1984). The New Science of Strong Materials or Why You Don't Fall Through the Floor (eissue ed.). Princeton University Press. ISBN 978-0-691-02380-9. Mathews, F.L. & Rawlings, R.D. (1999). Composite Materials: Engineering and Science. Boca Raton: CRC Press. ISBN 978-0-8493-0621-1. Lewis, P.R.; Reynolds, K. & Gagg, C. (2003). Forensic Materials Engineering: Case Studies. Boca Raton: CRC Press. ISBN 978-0-8493-1182-6. Wachtman, John B. (1996). Mechanical Properties of Ceramics. New York: Wiley-Interscience, John Wiley & Son's. ISBN 978-0-471-13316-2. Walker, P., ed. (1993). Chambers Dictionary of Materials Science and Technology. Chambers Publishing. ISBN 978-0-550-13249-9. Mahajan, S. (2015).
Absorption of exudate, to regulate the moisture level surrounding the wound- for example, dry gauzes absorb exudate strongly, drying the wound, hydrocolloids maintain a moist environment and film dressings do not absorb exudate; Gas permeability and exchange, especially with regard to oxygen and water vapour; Maintaining the optimum temperature to encourage healing; Mechanically debriding a wound to remove slough. Pressure dressings are commonly used to treat burns and after skin grafts. They apply pressure and prevent fluids from collecting in the tissue. Dressings can also regulate the chemical environment of a wound, usually with the aim of preventing infection by the impregnation of topical antiseptics. Commonly used antiseptics include silver and DACC,povidone-iodine, boracic lint dressings or historically castor oil. Antibiotics are also often used with dressings to prevent bacterial infection. Medical grade honey is another antiseptic option, and there is moderate evidence that honey dressings are more effective than common antiseptic and gauze for healing infected post-operative wounds. Bioelectric dressings can be effective in attacking certain antibiotic-resistant bacteria and speeding up the healing process. Dressings are also often impregnated with analgesics to reduce pain. The physical features of a dressing can impact the efficacy of such topical medications. Occlusive dressings, made from substances impervious to moisture such as plastic or latex, can be used to increase their rate of absorption into the skin.
== Fleet security and control == Recent advances in fleet management allow for the addition of over-the-air (OTA) security and control of fleet vehicles. Fleet Security and Control includes security of the vehicle while stopped or not in operation and the ability to safely disable a vehicle while in operation. This allows the fleet manager to recover stolen or rogue vehicles while reducing the chance of lost or stolen cargo. The additional of Fleet Security and Control to a fleet management system gives a fleet card manager preventative measures to address cargo damage and loss.
== Medicinal value == As far back as ancient times, Pliny the Elder had recognised that dried cherries have a diuretic effect; he mentioned them briefly in his description of medicinal plants found in books XX-XXVII of the Naturalis Historia.
Sources: en.wikipedia.org
small nuclear RNA (snRNA) A class of small non-coding RNA molecules, approximately 100–300 nucleotides in length and rich in uridine residues, found in association with specific proteins as part of ribonucleoprotein complexes known as snRNPs within nuclear speckles and Cajal bodies of the eukaryotic nucleus. SnRNPs assemble into larger complexes known as spliceosomes which play important roles in the splicing of pre-mRNA transcripts (hnRNAs) before they are exported to the cytoplasm.
However, in doubles, he and partner, Andrey Golubev, reached the semifinals where they lost to eventual champions John Isner and Jack Sock. Seeded second at the Miami Open, he reached the quarterfinals where he lost to sixth seed, world No. 8, and eventual finalist, Casper Ruud, in three sets. Zverev started his clay-court season at the Monte-Carlo Masters. Seeded second, he reached the semifinals after beating ninth seed and world No. 12, Jannik Sinner, in the quarterfinals in a three-set thriller. He lost in the semifinals to third seed, world No. 5, defending champion, and eventual champion, Stefanos Tsitsipas, in straight sets. As the top seed at the BMW Open in Munich, he was upset in the second round by world No. 70 and eventual champion, Holger Rune. Seeded second at the Madrid Open, he returned to defend his title. He reached the semifinals with a straight set win over eighth seed and world No. 10, Félix Auger-Aliassime, in the quarterfinals, after a tough three sets match win over Marin Čilić in the second round and Lorenzo Musetti's retirement in the third round due to a leg injury. In the semifinals, he took revenge on fourth seed, world No. 5, two-time Monte-Carlo champion, and 2019 finalist, Stefanos Tsitsipas, to reach his third final at this Masters 1000 event. He improved his ATP Head2Head record to 4–7 against Tsitsipas, earning his first clay-court win against him in the process. In the final, he was defeated by seventh seed and world No. 9, Carlos Alcaraz.
38 Mod 3): Nimitz-class aircraft carrier, Arleigh Burke-class destroyer, Ticonderoga-class cruiser, Oliver Hazard Perry-class frigate, Wasp-class amphibious assault ship, Tarawa-class amphibious assault ship, Whidbey Island-class dock landing ship, Harpers Ferry-class dock landing ship, Austin-class amphibious transport dock, Blue Ridge-class command ship, Cyclone-class patrol ship, Mark VI patrol boat Marine Corps: LAV-25 Coast Guard (Mk. 38 Mod 0, Mk. 38 Mod 2 and Mk. 38 Mod 3): Reliance-class cutter, Hamilton-class cutter, Sentinel-class cutter, Island-class cutter, USCGC Alex Haley, future Heritage-class cutter
Blood flows back to the heart in the systemic deep veins, with the flow of blood maintained by one-way valves in the deep veins, superficial veins, and in the perforator veins. The venous valves serve to prevent regurgitation (backflow) due to the low pressure of veins, and the pull of gravity. They also serve to prevent the over-widening of the vein. A venous valve is bicuspid (having two leaflets) and is formed by an infolding of part of the tunica intima on either side of the lumen of the veins. The leaflets are strengthened with collagen and elastic fibres, and covered with endothelium. The endothelial cells on the surfaces of the leaflets facing the vein wall, are arranged transversely. On the leaflet surfaces that open to let the blood flow, the cells are arranged longitudinally in the direction of the flow. The leaflets are attached to the venous wall at their convex edges. Their margins are concave and are directed with the flow lying against the wall. As the valve forms, the vein wall where the leaflets attach, becomes dilated on each side. These widenings form the pockets, hollow cup-shaped regions, on the cardial side, known as the valvular sinuses. The endothelial cells in the sinuses are able to stretch twice as much as those in areas without valves. When the blood tries to reverse its direction (due to low venous pressure and the pull of gravity), the sinuses fill first closing the leaflets and keeping them together. Approximately 95% of the venous valves are in the small veins of less than 300 micrometres.
The motor proteins actin and myosin generate the forces exerted by contracting muscles. Cortisol decreases amino acid uptake by muscle and inhibits protein synthesis. Current recommendations suggest that bodybuilders should consume 25–30% of protein per total calorie intake to further their goal of maintaining and improving their body composition. This is a widely debated topic, with many arguing that 1 gram of protein per pound of body weight per day is ideal, some suggesting that less is sufficient, while others recommending 1.5, 2, or more. It is believed that protein needs to be consumed frequently throughout the day, especially during/after a workout, and before sleep. There is also some debate concerning the best type of protein to take. Chicken, turkey, beef, pork, fish, eggs and dairy foods are high in protein, as are some nuts, seeds, beans, and lentils. Casein or whey are often used to supplement the diet with additional protein. Whey is the type of protein contained in many popular brands of protein supplements and is preferred by many bodybuilders because of its high biological value (BV) and quick absorption rates. Whey protein also has a bigger effect than casein on insulin levels, triggering about double the amount of insulin release. That effect is somewhat overcome by combining casein and whey.
Sources: en.wikipedia.org
==== Mechanisms of plasticity ==== To understand mechanisms of activity-dependent plasticity, Sur’s lab used microarray analyses of classic visual plasticity paradigms (dark-rearing and monocular deprivation during the critical period) to discover gene expression changes and microRNAs associated with cortical plasticity. They demonstrated rules of plasticity and the role of specific molecules in implementing these rules. His lab showed that neuronal plasticity is implemented by locally coordinated potentiation and depression of spines, which involves AMPA receptor redistribution via targeted expression of Arc. Together with large-scale synaptic dynamics of V1 neurons during normal development, these findings have demonstrated a fundamental principle, that Hebbian strengthening of coactive synapses and heterosynaptic weakening of adjacent synapses cooperatively mediate neuron-wide plasticity.
== Anti-nRNP antibody == Anti-nuclear Ribonucleoprotein (Anti-nRNP) antibodies are a type of autoantibody, which are antibodies that wrongly target and attack a person's own cells, proteins or tissues. In particular, anti-nRNPs are directed against nuclear ribonucleoproteins (nRNPs), which are complexes composed of proteins and nucleic acids. These ribonucleoproteins play a critical role in various cellular processes, including RNA processing and gene expression. Anti-U1 RNP antibodies target proteins that are part of the U1 small nuclear ribonucleoprotein (U1-snRNP) complex. This complex is involved in RNA splicing, a process that removes non-coding regions from pre-messenger RNA before it is translated into proteins. Because RNA splicing is necessary for normal cell function, problems involving the U1-snRNP complex are associated with several autoimmune connective tissue diseases. Although researchers do not understand why anti-U1 RNP antibodies develop, studies suggest that both genetic and environmental factors contribute to the loss of immune tolerance that allows these antibodies to form.
== Diagnosis == The clinical diagnosis of BPD can be made through a psychiatric assessment conducted by a mental health professional, ideally a psychiatrist or psychologist. This comprehensive assessment integrates various sources of information to confirm the diagnosis, encompassing the patient's self-reported clinical history, observations made by the clinician during interviews, and corroborative details obtained from family members, friends, and medical records. Patients should be thoroughly assessed for co-morbid mental health conditions, substance use disorders, suicidal ideation, and any self-harming behaviors. An effective approach involves presenting the criteria of the disorder to the individual and inquiring if they perceive these criteria as reflective of their experiences. Involving individuals in the diagnostic process may enhance their acceptance of the diagnosis. Despite the stigma associated with BPD and previous notions of its untreatability, disclosing the diagnosis to individuals is generally beneficial. It provides them with validation and directs them to appropriate treatment options. The psychological evaluation for BPD typically explores the onset and intensity of symptoms and their impact on the individual's quality of life. Critical areas of focus include suicidal thoughts, self-harm behaviors, and any thoughts of harming others. The diagnosis relies on both the individual's self-reported symptoms and the clinician's observations.
== Pressure instrumentation == Oil, gas and petrochemical processes are undertaken at specific operating pressures. Pressure is measured by pressure sensors (PE) which send pressure (PT) signals to pressure controllers (PIC). Pressure vessels and tanks are fitted with local pressure indicators (PI). In the petrochemical industry pressure is controlled by maintaining a constant pressure in the upper gas space of a vessel. A pressure controller (PIC) adjusts the setting on a pressure control valve (PCV) that feeds gas forward to the next stage of the process. A rising pressure in the vessel results in the PCV opening to feed more gas forward. If the pressure continues to rise some controllers then act to open a second PCV that feeds excess gas to the flare system. The pressure transmitter is configured to provide warning alarms (PAL and PAH) if the pressure exceeds set high and low limits. If these limits are exceeded (PALL and PAHH) an automatic shutdown of the system is initiated which includes closure of the inlet valves of the vessel. The pressure sensor (PT) that initiates a shutdown is a separate instrument loop from the PT associated with the pressure control loop to mitigate common mode failures and to ensure greater reliability of the shutdown function. The operation of hydrocyclones is controlled by pressure instrumentation that maintains fixed differential pressures between the inlet and the oil and water outlets. Turbo-expanders are controlled by maintaining the inlet pressure (PIC) at a constant value by controlling the angle of the expander inlet vanes.
Sources: en.wikipedia.org
No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.
It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.
The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.
Lyophilized material is typically kept refrigerated and away from light in the sealed vial provided. Dissolved material is generally used within a limited period rather than stored long term.